8-K: Mustang Bio Terminates Lease Agreement, Sells Assets to AbbVie for $1 Million

Mustang Bio sells furniture, fixtures, and equipment to AbbVie for $1 million and terminates its lease agreement, potentially saving $2 million in lease-related payments.

Summary

• Mustang Bio entered into a Bill of Sale and Surrender Agreement with AbbVie, effective January 31, 2025, to sell certain furniture, fixtures, and equipment (FF&E) at its Worcester, Massachusetts location for $1.0 million.
• As part of the agreement, AbbVie will lease the premises from the landlord following the termination of Mustang Bio's lease.
• Mustang Bio is required to vacate the premises within 20 business days following the Effective Date.
• AbbVie has an inspection period to assess the condition of the FF&E and can issue an Acceptance or Rejection Notice.
• The purchase price may be reduced proportionally if the FF&E is not in acceptable condition, with specific thresholds for furniture and all FF&E items.
• An Escrow Agreement was established to manage the disbursement of the Purchase Price.
• Mustang Bio also entered into a First Amendment to Lease Agreement with the Landlord to terminate the lease early, potentially saving approximately $2.0 million in lease-related payments and obligations.
• The early termination is contingent on the Transfer Date as defined in the Sale/Surrender Agreement or the date the Company surrenders the Premises to the Landlord.
• Mustang Bio waived its right to exercise extension options under the Lease.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is receiving $1 million, it is also giving up assets and potentially reducing its operational capacity. The potential savings of $2 million are positive, but contingent.

Positives

• Mustang Bio receives $1.0 million from the sale of FF&E.
• The company anticipates potential savings of approximately $2.0 million in lease-related payments and obligations due to the early lease termination.

Risks

• The Sale/Surrender Agreement could be terminated if AbbVie and Mustang Bio do not agree on a Purchase Price reduction after a Rejection Notice.
• The Early Termination Date may not occur, and the Base Term of the Lease shall not be subject to early termination.
• The potential savings of $2.0 million are contingent on the Early Termination Date occurring.

Future Outlook

The company anticipates potential savings of approximately $2.0 million in lease-related payments and obligations if the lease is terminated pursuant to the Amendment. The company undertakes no obligation to publicly update or revise any forward-looking statements.

Industry Context

This announcement reflects a strategic decision by Mustang Bio to reduce its operational footprint and potentially improve its financial position. Such moves are common in the biotech industry as companies manage resources and adapt to changing research and development needs.

Comparison to Industry Standards

• It is difficult to compare this specific transaction to industry standards without knowing the specifics of the FF&E being sold and the lease terms.
• However, similar transactions involving the sale of lab equipment and lease terminations are common in the biotech industry.
• For example, other biotech companies might sublease unused lab space or sell surplus equipment to generate revenue and reduce costs.

Stakeholder Impact

• Shareholders may view the asset sale and lease termination as a positive step towards improving the company's financial position.
• Employees at the Worcester location may be affected by the relocation.
• The landlord will have a new tenant, AbbVie, for the premises.

Next Steps

• Mustang Bio must vacate the premises within 20 business days following the Effective Date.
• AbbVie will inspect the premises and FF&E within the Inspection Period.
• AbbVie and Mustang Bio will negotiate any Purchase Price reduction if the FF&E is not in acceptable condition.
• The Escrow Agent will disburse the Purchase Price according to the terms of the Escrow Agreement.

Key Dates